`
`
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`
`
`
`
`
`
`MEDTRONIC, INC., AND MEDTRONIC VASCULAR, INC.
`Petitioners,
`
`v.
`
`TELEFLEX INNOVATIONS S.A.R.L.
`Patent Owner.
`
`
`
`
`Case IPR2020-01341 (Patent 8,142,413)
`Case IPR2020-01343 (Patent RE 46,116)
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Declaration of Mark Goemer
`
`I, Mark Goemer, hereby declare as follows:
`
`I previously submitted a declaration in connection with the following IPRs
`
`before the Patent Trial and Appeal Board: IPR2020-00126, IPR2020-00128,
`
`IPR2020-00129, IPR2020-00132, IPR2020-00134, IPR2020-00135, and IPR2020-
`
`00137. My statements from my original declaration dated September 21, 2020,
`
`attached hereto as Appendix A, remain true and correct, and I hereby adopt and
`
`submit them in connection with the following IPRs before the Patent Trial and
`
`Appeal Board: IPR2020-01341 and IPR2020-01343.
`
`
`
`I declare under penalty of perjury under the laws of the United States of
`
`America that the foregoing is true and correct.
`
`Dated: May {Ll
`
`, 2021
`
`Mark Goemer
`
`Page 2
`
`Teleflex EX. 2120
`
`Medtronic v. Teleflex
`
`
`
`
`
`
`
`
`
`
`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`
`
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`
`
`
`
`
`
`MEDTRONIC, INC., AND MEDTRONIC VASCULAR, INC.
`Petitioners,
`
`v.
`
`TELEFLEX INNOVATIONS S.A.R.L.
`Patent Owner.
`
`
`
`
`
`
`
`
`
`
`
`
`DECLARATION OF MARK GOEMER
`
`
`
`
`
`
`
`APPENDIX A
`
`
`
`
`
`I, Mark Goemer, declare as follows:
`1. My name is Mark Goemer. I am a Spectralytics employee. I am
`
`currently the Director of Sales at Spectralytics and Meier Tool and Engineering. I
`
`began working at Spectralytics in 2004 in a sales role. I eventually was promoted
`
`to the position of Sales Manager, and ultimately to the position of Director of
`
`Sales.
`
`2. My compensation does not depend in any way on the outcome of this
`
`proceeding. I have not been offered any payment, incentive, or inducement to
`
`provide this Declaration.
`
`3.
`
`I have personal knowledge of the facts set forth in this Declaration,
`
`except as otherwise stated. I am competent to testify as to all matters stated, and if
`
`called upon to do so, I would testify to the facts set forth in this Declaration.
`
`4.
`
`Spectralytics provides laser processing solutions to its customers
`
`worldwide. This includes custom laser cutting of stainless steel and other materials
`
`with critical tolerances.
`
`5. My responsibilities at Spectralytics include working closely with
`
`customers to understand and service their laser cutting needs. In this role, I have
`
`knowledge of and review the documents created and received in the process of
`
`performing work on behalf of our customers. These documents include sales
`
`acknowledgements, customer prints, and certificates of completion.
`
`
`
`1
`
`
`
`
`
`6.
`
`I personally recall several jobs that Spectralytics performed for
`
`Vascular Solutions in the 2005 time period. That work included laser cutting parts
`
`for prototypes of a product that Vascular Solutions was developing.
`
`7.
`
`Exhibit 2095 contains true and accurate copies of a Sales
`
`Acknowledgement for an order placed on March 21, 2005 by Vascular Solutions,
`
`and two Certificates of Completion for that job, dated April 5, 2005 and April 4,
`
`2005 respectively. It is the regular practice of Spectralytics to create a Sales
`
`Acknowledgment for a sales order. It also is the regular practice of Spectralytics to
`
`create a Certificate of Completion upon the cleaning, visual inspection,
`
`dimensional inspection, electropolish, and final inspection/audit of a product prior
`
`to shipping to the customer. These documents have been maintained in the
`
`ordinary course of business at Spectralytics and were retrieved from Spectralytics’
`
`files.
`
`8.
`
`The order reflected in Exhibit 2095 was for laser cutting of stainless
`
`steel hypotubing and electropolishing. Spectralytics does not itself manufacture
`
`stainless steel hypotubing, but instead would have received hypotubes from
`
`Vascular Solutions or directly from a different vendor and then laser cut and
`
`electropolished them according to Vascular Solutions’ specifications. Based on
`
`my knowledge of Spectralytics’ work on behalf of Vascular Solutions, along with
`
`the quantity and nature of the order, including the reference to an “X” number for
`
`
`
`2
`
`
`
`
`
`the part, I know that this order was for parts to be used in prototypes that Vascular
`
`Solutions was building.
`
`9.
`
`Exhibit 2113 contains true and accurate copies of the prints from
`
`Vascular Solutions for the order shown in Exhibit 2095. It is the regular practice
`
`of Spectralytics to obtain a customer print (or prints) for every custom order, like
`
`those reflected in Exhibit 2113. These prints shown in Exhibit 2113 have been
`
`maintained in the ordinary course of business at Spectralytics and were retrieved
`
`from Spectralytics’ files.
`
`10. Exhibit 2111 contains true and accurate copies of a Sales
`
`Acknowledgment for an order placed on June 23, 2005 by Vascular Solutions and
`
`a Certificate of Completion for that job dated July 27, 2005. The documents in
`
`Exhibit 2111 have been maintained in the ordinary course of business at
`
`Spectralytics and were retrieved from Spectralytics’ files. This was a second order
`
`for laser cutting of stainless steel hypotubing placed by Vascular Solutions. Here
`
`again, Spectralytics does not itself manufacture stainless steel hypotubing, but
`
`instead would have received hypotubes from Vascular Solutions or directly from a
`
`different vendor, and then laser cut and electropolished them according to Vascular
`
`Solutions’ specifications. As with the first order, based on my knowledge of
`
`Spectralytics’ work on behalf of Vascular Solutions, along with the quantity and
`
`nature of the order, including the reference to an “X” number for the part, I know
`
`
`
`3
`
`
`
`that this order was for parts to be used in prototypes that Vascular Solutions was
`
`building.
`
`11.
`
`Exhibit 21 14 is a true and accurate copy of the print from Vascular
`
`Solutions for the order shown in Exhibit 2111. As explained above, it is the
`
`regular practice of Spectralytics to obtain a customer print (or prints) for every
`
`custom order, like that reflected in Exhibit 2114. The print shown in Exhibit 21 14
`
`has been maintained in the ordinary course of business at Spectralytics and was
`
`retrieved from Spectralytics’ files.
`
`12.
`
`Exhibit 21 15 contains true and accurate copies of additional prints
`
`from Vascular Solutions that have been maintained in the ordinary course of
`
`business at Spectralytics and have been retrieved from Spectralytics’ files.
`
`13.
`
`I declare under penalty of perjury under the laws of the United States
`
`of America that the foregoing is true and correct.
`
`Executed on this 9x i day of September, 2020
`
`
`
`Q%r\
`
`Mark Goemer
`
`Page 7
`
`Teleflex Ex. 2120
`Medtronic v. Teleflex
`
`